Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Cost of RevenueGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Guided Therapeutics (GTHP) Cost of Revenue (2016 - 2025)

Guided Therapeutics' Cost of Revenue history spans 16 years, with the latest figure at $105000.0 for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 149.3% to $105000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $251000.0, a 218.96% increase, with the full-year FY2025 number at $169000.0, up 3280.0% from a year prior.
  • Cost of Revenue hit $105000.0 in Q4 2025 for Guided Therapeutics, up from $22000.0 in the prior quarter.
  • Over the last five years, Cost of Revenue for GTHP hit a ceiling of $222000.0 in Q4 2023 and a floor of -$213000.0 in Q4 2024.
  • Historically, Cost of Revenue has averaged $28117.6 across 5 years, with a median of $37000.0 in 2022.
  • Biggest five-year swings in Cost of Revenue: plummeted 380.0% in 2022 and later surged 3550.0% in 2025.
  • Tracing GTHP's Cost of Revenue over 5 years: stood at -$10000.0 in 2021, then plummeted by 380.0% to -$48000.0 in 2022, then soared by 562.5% to $222000.0 in 2023, then crashed by 195.95% to -$213000.0 in 2024, then skyrocketed by 149.3% to $105000.0 in 2025.
  • Business Quant data shows Cost of Revenue for GTHP at $105000.0 in Q4 2025, $22000.0 in Q3 2025, and $51000.0 in Q2 2025.